Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 412-415

  Gardner, Erin R ^a   Sparreboom, Alex ^b,c   Verweij, Jaap ^d   Figg, William D ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABCB1; ABCG2; Imatinib; Pharmacokinetics

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG LIVER LEVEL; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; STEADY STATE; UPREGULATION; WESTERN BLOTTING;

EID: 45349103388     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5412     Document Type: Article

References (26)

1. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clinical pharmacokinetics 2005; 44:879-94.
2. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. The lancet oncology 2003; 4:75-85.
3. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw 2005; 3:757-68.
4. Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer chemotherapy and pharmacology 2005; 55:379-86.
5. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109:3496-9.
6. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473-5.
7. Sohn SK, Moon JH, Cho YY, Chae YS, Kim JG, Lee KS, Hong SP, Kim SO. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance. Leukemia & lymphoma 2007; 48:1659-61.
8. Burger H, Nooter K. Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib. Cell Cycle 2004; 3.
9. Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. The Journal of pharmacology and experimental therapeutics 2003; 307:824-8.
10. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer research 2004; 64:2333-7.
11. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer research 2001; 61:3458-64.
12. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005; 6:115-38.
13. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer biology & therapy 2005; 4:747-52.
14. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. Journal of the National Cancer Institute 2004; 96:46-55.
15. Gardner ER, Smith NF, Sparreboom A, Figg WD. Influence of the Dual ABCB1 and ABCG2 Inhibitor Tariquidar on the Disposition of Oral Imatinib in Mice. Submitted.
16. Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, Klein MA, Schatzl HM. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. The Journal of biological chemistry 2004; 279:41918-27.
17. Wakabayashi K, Nakagawa H, Tamura A, Koshiba S, Hoshijima K, Komada M, Ishikawa T. Intramolecular disulfide bond is a critical checkpoint determining degradative fates of ABC transporter ABCG2 protein. The Journal of biological chemistry 2007.
18. Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2007.
19. Martignoni M, Groothuis G, de Kanter R. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug metabolism and disposition: the biological fate of chemicals 2006; 34:1047-54.
20. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clinical pharmacology and therapeutics 2006; 80:192-201.
21. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clinical pharmacology and therapeutics 2007; 82:33-40.
22. Jorgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002; 99:713-5.
23. le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt C, Schwarz M, Muller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood cells, molecules & diseases 2002; 28:75-85.
24. Le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. American journal of hematology 2003; 73:249-55.
25. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004; 10:8341-50.
26. Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006; 12:6073-8.